JP2013509441A - 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用 - Google Patents

記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用 Download PDF

Info

Publication number
JP2013509441A
JP2013509441A JP2012537154A JP2012537154A JP2013509441A JP 2013509441 A JP2013509441 A JP 2013509441A JP 2012537154 A JP2012537154 A JP 2012537154A JP 2012537154 A JP2012537154 A JP 2012537154A JP 2013509441 A JP2013509441 A JP 2013509441A
Authority
JP
Japan
Prior art keywords
subject
day
ginarine
administered
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012537154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509441A5 (enExample
Inventor
ツァイ，リー−ウェイ
グァン，チー−ソン
ハガーティー，ステファン，ジェイ．
ホルソン，エドワード
ワーグナー，フローレンス
グレフ，ヨハネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Broad Institute Inc
Original Assignee
Broad Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Institute Inc filed Critical Broad Institute Inc
Publication of JP2013509441A publication Critical patent/JP2013509441A/ja
Publication of JP2013509441A5 publication Critical patent/JP2013509441A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2012537154A 2009-10-30 2010-10-29 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用 Pending JP2013509441A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25692709P 2009-10-30 2009-10-30
US61/256,927 2009-10-30
US26546809P 2009-12-01 2009-12-01
US61/265,468 2009-12-01
PCT/US2010/054872 WO2011053876A1 (en) 2009-10-30 2010-10-29 The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders

Publications (2)

Publication Number Publication Date
JP2013509441A true JP2013509441A (ja) 2013-03-14
JP2013509441A5 JP2013509441A5 (enExample) 2013-12-19

Family

ID=43922604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012537154A Pending JP2013509441A (ja) 2009-10-30 2010-10-29 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用

Country Status (9)

Country Link
US (2) US8563615B2 (enExample)
EP (1) EP2493298A4 (enExample)
JP (1) JP2013509441A (enExample)
CN (1) CN102834002A (enExample)
AU (1) AU2010313255B2 (enExample)
CA (1) CA2779497A1 (enExample)
IN (1) IN2012DN03807A (enExample)
NZ (1) NZ599757A (enExample)
WO (1) WO2011053876A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510947A (ja) * 2020-01-24 2023-03-15 ユニバーシティ オブ レスター Ｈｄａｃ分解剤

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
JP2013509441A (ja) 2009-10-30 2013-03-14 マサチューセッツ インスティテュート オブ テクノロジー 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
CA2834548C (en) 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
US8691875B2 (en) * 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
SI2734510T1 (sl) 2011-07-22 2019-05-31 Massachusetts Institute Of Technology Aktivatorji histon deacetilaz (HDACS) razreda I in njihove uporabe
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2014046871A1 (en) * 2012-09-04 2014-03-27 Massachusetts Institute Of Technology The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN112062826A (zh) * 2020-06-01 2020-12-11 暨南大学 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用
WO2023034440A1 (en) * 2021-09-01 2023-03-09 Case Western Reserve University Treatment of neurodegenerative diseases with hdac inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
EP1212357B1 (en) 1999-09-08 2007-05-02 Sloan-Kettering Institute For Cancer Research Crystal structure of a deacetylase and inhibitors thereof
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
EP1748046A3 (en) 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
JP4975941B2 (ja) * 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
US20060148743A1 (en) 2001-05-18 2006-07-06 Vasant Jadhav RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
AU2002318364A1 (en) 2001-06-14 2003-01-02 Bristol-Myers Squibb Company Novel human histone deacetylases
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
AU2002361022A1 (en) 2001-12-07 2003-06-17 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
AU2003209060A1 (en) 2002-02-07 2003-09-02 Axys Pharmaceuticals, Inc. Assay for acytyltransferase or deacetylase activity
AU2003214055A1 (en) 2002-02-08 2003-09-02 Novartis Ag Method for screening for compounds having hdac inhibitory activity
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US20050288227A1 (en) 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US20030224473A1 (en) 2002-05-23 2003-12-04 Mccafferty Dewey G. Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
AU2003273701A1 (en) 2002-10-17 2004-05-04 Methylgene Inc. Inhibitors of histone deacetylase
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
WO2005048942A2 (en) * 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
MXPA06010900A (es) 2004-03-26 2007-02-21 Methylgene Inc Inhibidores de histona desacetilasa.
WO2005102358A2 (en) * 2004-04-20 2005-11-03 Rnd Pharmaceuticals Silicone-substituted cox-2 selective inhibitors
DK1591109T3 (da) 2004-04-30 2008-10-06 Topotarget Germany Ag Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
US20060008517A1 (en) * 2004-07-09 2006-01-12 Lynch Marina A Treatment of age-related memory impairment
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
US20060160902A1 (en) 2004-11-08 2006-07-20 Wiech Norbert L Histone deacetylase inhibitors
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070015183A1 (en) 2005-06-03 2007-01-18 The General Hospital Corporation Biomarkers for huntington's disease
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP1937236A2 (en) * 2005-09-07 2008-07-02 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
WO2007055942A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Substituted nicotinamide compounds
WO2007056435A2 (en) * 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
WO2007100657A2 (en) 2006-02-28 2007-09-07 Merck & Co., Inc. Inhibitors of histone deacetylase
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
EP2023924B1 (en) 2006-05-18 2016-08-03 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
US20100112600A1 (en) 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US8088951B2 (en) * 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
US20110009475A1 (en) * 2007-07-13 2011-01-13 Massachusetts Institute Of Technology Methods for treating stress induced emotional disorders
WO2009154697A2 (en) * 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
KR20110033304A (ko) * 2008-07-23 2011-03-30 메사추세츠 인스티튜트 오브 테크놀로지 Ｄｎａ 손상에 대해 보호하고 신경세포 생존을 증가시키는 히스톤 디아세틸라제 1 (ｈｄａｃ1)의 활성화
NZ593447A (en) * 2008-12-03 2012-12-21 Harvard College Inhibition of hdac2 to promote memory
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
JP2013509441A (ja) * 2009-10-30 2013-03-14 マサチューセッツ インスティテュート オブ テクノロジー 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用
SI2734510T1 (sl) * 2011-07-22 2019-05-31 Massachusetts Institute Of Technology Aktivatorji histon deacetilaz (HDACS) razreda I in njihove uporabe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049262A1 (en) * 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014045460; Ｃｕｒｒ．　Ｄｒｕｇ　Ｔａｒｇｅｔｓ　ＣＮＳ　Ｎｅｕｒｏｌ．　Ｄｉｓｏｒｄ． Ｖｏｌ．４, 2005, ｐｐ．４１-５０ *
JPN6014045462; Ｃａｎｃｅｒ　Ｉｎｖｅｓｔ． Ｖｏｌ．２２　Ｎｏ．６, 2004, ｐｐ．８８６-８９６ *
JPN6014045464; Ｅｘｐｅｒｔ　Ｏｐｉｎ．　Ｉｎｖｅｓｔ．　Ｄｒｕｇｓ Ｖｏｌ．１８　Ｎｏ．５, 200905, ｐｐ．５７３-５８４ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510947A (ja) * 2020-01-24 2023-03-15 ユニバーシティ オブ レスター Ｈｄａｃ分解剤
JP7611593B2 (ja) 2020-01-24 2025-01-10 ユニバーシティ オブ レスター Ｈｄａｃ分解剤

Also Published As

Publication number Publication date
AU2010313255B2 (en) 2015-04-30
AU2010313255A1 (en) 2012-05-31
IN2012DN03807A (enExample) 2015-08-28
EP2493298A4 (en) 2013-04-10
WO2011053876A1 (en) 2011-05-05
CN102834002A (zh) 2012-12-19
US20120322879A1 (en) 2012-12-20
CA2779497A1 (en) 2011-05-05
EP2493298A1 (en) 2012-09-05
NZ599757A (en) 2014-08-29
US8841346B2 (en) 2014-09-23
US8563615B2 (en) 2013-10-22
US20110224303A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
JP2013509441A (ja) 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用
JP7042244B2 (ja) ヒストンデアセチラーゼ阻害剤
US8088951B2 (en) Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US11377423B2 (en) Inhibitors of histone deacetylase
US10793538B2 (en) Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JP2012510512A (ja) 記憶を推進するためのｈｄａｃ２の阻害
WO2005108367A1 (en) Compounds for treatment of neurodegenerative diseases
JP2020059733A (ja) ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
US20190336488A1 (en) Use of pridopidine for the treatment of fragile x syndrome
US20240065988A1 (en) Combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
CA2692775C (en) Methods of enhancing cognitive function using non-peptidic compounds
US12611387B2 (en) Compound and composition for inducing neuroprotection
JP2024097004A (ja) 陰性症状および障害を処置するため、神経可塑性を増大するため、ならびに神経保護を促進するためのロルペリドンの使用
Diniz et al. Histone deacetylase inhibition mitigates cognitive deficits and astrocyte dysfunction induced by amyloid‐β (Aβ) oligomers
JP2020500216A (ja) 運動ニューロン疾患の治療のためのガングリオシド代謝阻害剤
JP2011518188A (ja) リソソーム調節のための化合物および使用方法
JP2024510632A (ja) スパイン形成のためのある特定のファスシン結合化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151020